In Brief: Visx
This article was originally published in The Gray Sheet
Visx: Excimer laser manufacturer says it will report higher than predicted fourth-quarter 1997 earnings, following a Dec. 16 announcement that the firm has stopped making certain royalty payments to Pillar Point Partners, a joint venture with laser maker Summit Technology. "Commencing in October 1997, the company no longer pays royalties to Pillar Point for certain patented procedures performed using the Visx excimer laser system which have not been approved by FDA," Visx explains. "This is consistent with a provision in the agreement which provides that royalties are due only for FDA-approved procedures." A November lawsuit filed by Visx in a Santa Clara County, California state court seeking declaratory judgment is pending...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.